Ayahuasca: An ancient sacrament for treatment of contemporary psychiatric illness? [0.03%]
亚叶黄esserium：一种古老的圣餐可治疗现代精神病吗？
Benjamin J Malcolm,Kelly C Lee
Benjamin J Malcolm
Ayahuasca is a traditional psychoactive sacrament that's been used in Amazonian shamanic rituals for hundreds of years. Ayahuasca is notorious for its psychedelic properties produced from the combination of monoamine oxidase inhibitors (MAO...
Evidence for the use of "medical marijuana" in psychiatric and neurologic disorders [0.03%]
医用大麻在精神疾病和神经性疾病中的应用证据
Christopher Noel
Christopher Noel
Introduction: Cannabis is listed as a Schedule I substance under the Controlled Substances Act of 1970, meaning the US federal government defines it as an illegal drug that has high potential for abuse and no established ...
Clinical potential of psilocybin as a treatment for mental health conditions [0.03%]
裸盖菇素治疗精神疾病的临床潜力
Jeremy Daniel,Margaret Haberman
Jeremy Daniel
Psilocybin, a classic hallucinogen, is a chemical produced by more than 100 species of mushrooms worldwide. It has high affinity for several serotonin receptors, including 5-HT1A, 5-HT2A, and 5-HT2C, located in numerous areas of the brain, ...
Ketamine for the treatment of major depressive disorder and bipolar depression: A review of the literature [0.03%]
氯胺酮治疗抑郁症和双相抑郁的疗效评估
Sarah E Grady,Travis A Marsh,Allison Tenhouse et al.
Sarah E Grady et al.
Introduction: Over the past decade, ketamine has been studied for major depressive disorder and bipolar depression. Ketamine is believed to exert its antidepressant properties through N-methyl-D-aspartate receptor antagon...
Valproate serum concentrations in patients with hypoalbuminemia and medical complications [0.03%]
血清白蛋白降低患者中 valproate 血药浓度的测定及医疗并发症的影响
Amy VandenBerg,Jessica Broadway,Callie Lalich et al.
Amy VandenBerg et al.
Introduction: Valproic acid (VPA) and its derivatives are highly protein bound with free fraction increasing with dose and serum concentration. Consensus guidelines regarding dose adjustment for hypoalbuminemia are not av...
Enteral administration of protein supplement and valproate: A potential pharmacokinetic interaction [0.03%]
蛋白补充剂和丙戊酸的肠内给药：一种潜在的药物动力学相互作用
Amy VandenBerg,Jessica Broadway
Amy VandenBerg
Background: Valproic acid (VPA) and its derivatives are highly protein bound. Certain highly protein bound medications (eg, phenytoin) have specific administration instructions for patients on enteral nutrition supplement...
Nicole East,Megan Maroney
Nicole East
Background: Prader-Willi syndrome (PWS), a neurologic disorder caused by a mutation of chromosome 15, is characterized by such symptoms as hypotonia, hypogonadism, hyperphagia, cognitive impairment, and difficult behavior...
Metabolic monitoring in children 5 years of age and younger prescribed second-generation antipsychotic medications [0.03%]
5岁及以下儿童使用第二代抗精神病药物的代谢监测
Yardlee S Kauffman,Thomas Delate,Sheila Botts
Yardlee S Kauffman
Introduction: The objective of this article was to identify the rates of patients ≤5 years of age who received recommended monitoring before and after second-generation antipsychotic (SGA) initiation and had an SGA metab...
Stephanie Dwyer,Robin Hieber
Stephanie Dwyer
Bupropion is an antidepressant thought to have a reduced risk of inducing mood switching as compared to other antidepressants. Minimal information is available on the induction of mood shifts when used for smoking cessation. This case descr...
Evaluation of the use of low-dose quetiapine and the risk of metabolic consequences: A retrospective review [0.03%]
低剂量喹硫平的使用及其代谢风险的评估：回顾性研究
Chelsea N Carr,Shruti Lopchuk,Mary E Beckman et al.
Chelsea N Carr et al.
Introduction: Quetiapine fumarate is an atypical antipsychotic approved for the treatment of schizophrenia, major depressive disorder, and bipolar disorder. Due to the sedative effects observed at low doses, prescribers u...